This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Sell Your FANGMAN Stocks?
by Tracey Ryniec
Tracey and Kevin discuss the rocky 2022 stock market and the future of growth stocks.
Can AbbVie's (ABBV) New Drugs Make up for Lost Humira Sales?
by Zacks Equity Research
AbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new indications. They are expected to drive revenues once Humira loses U.S. exclusivity in 2023.
Can Biogen (BIIB) Navigate Multiple Challenges & Grow Again?
by Zacks Equity Research
Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, we are hopeful that potential new product launches such as lecanemab, zuranolone and additional biosimilars can help revive growth.
Biotech Stock Roundup: BIIB's AD Drug Data & REGN, IONS, VRTX's Updates
by Zacks Equity Research
Regulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week.
LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data
by Ekta Bagri
The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.
Stock Market News for Sep 29, 2022
by Zacks Equity Research
Wall Street closed sharply higher on Wednesday rebounding from a six-day losing streak.
Biogen's (BIIB) Lecanemab Meets Goal in Alzheimer's Study
by Zacks Equity Research
Biogen (BIIB) and Eisai's Clarity AD study showed that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of clinical decline on the CDR-SB scale by 27% compared to placebo.
Ionis' (IONS) Hypercholesterolemia Drug Not to Enter Phase III
by Zacks Equity Research
Ionis (IONS) posts data from the phase IIb SOLANO study on ION449 for treating hypercholesterolemia. Though the study met the primary endpoint, ION449 will not advance into phase III development.
Alnylam (ALNY) Soars 8.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Alnylam (ALNY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Biogen Inc. (BIIB) Stock Moves -0.36%: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed the most recent trading day at $195.38, moving -0.36% from the previous trading session.
Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed the most recent trading day at $204.83, moving +1.51% from the previous trading session.
Biogen Inc. (BIIB) Up 1.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
How Are Biotech ETFs Reacting to Q2 Earnings Releases?
by Sanghamitra Saha
he Biotech sector has been in a sweet spot for quite some time now. Plus, earnings releases have also come in mostly upbeat.
Eli Lilly's (LLY) Potential New Products Key to Growth
by Zacks Equity Research
Lilly (LLY) expects to launch five new medicines by 2023 end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.
Ionis (IONS) Q2 Earnings & Sales Miss Estimates, Stock Down
by Zacks Equity Research
Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.
Denali (DNLI) Q2 Earnings Beat, Pipeline Progress in Focus
by Zacks Equity Research
Denali (DNLI) incurs narrower-than-expected Q2 loss while collaboration revenues beat estimates.
Is VanEck Morningstar Wide Moat ETF (MOAT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for MOAT
Should VanEck Morningstar Wide Moat ETF (MOAT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for MOAT
AbbVie's (ABBV) Q2 Earnings Beat Estimates, Revenues Lag
by Zacks Equity Research
AbbVie's earnings (ABBV) beat estimates for second-quarter 2022, while sales miss the same. ABBV's immunology and neuroscience drugs drive sales. Shares decline in pre-market trading.
Biotech Stock Roundup: BMY, BIIB's Q2 Earnings, GILD's Updates & More
by Zacks Equity Research
Earnings updates from Bristol Myers (BMY) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.
Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More
by Zacks Equity Research
Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Biogen Inc. (BIIB) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Biogen Inc. (BIIB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BIIB vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BIIB vs. ILMN: Which Stock Is the Better Value Option?
Ionis (IONS) Partner Wraps Up Cardiovascular Study Enrollment
by Zacks Equity Research
Ionis' (IONS) partner, Novartis completes enrolling patients in a phase III study on pelacarsen for treating cardiovascular disease due to elevated Lp(a) levels. Data from this study is expected in 2025.